Martin Auster
Stock Analyst at UBS
(2.16)
# 2,701
Out of 4,711 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $65.66 | +82.76% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $44.22 | +137.45% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $4.35 | +497.70% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $4.16 | +2,784.62% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $4.70 | +6,282.98% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $11.68 | +396.58% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $359.58 | -45.49% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.62 | +5,949.38% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $70.44 | -14.82% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $44.78 | +45.15% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $118.97 | -38.64% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $2.87 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $16.98 | +359.36% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.19 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $9.01 | +377.25% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $31.82 | +6.85% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $12.18 | +72.41% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $14.55 | +9.97% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $65.66
Upside: +82.76%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $44.22
Upside: +137.45%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $4.35
Upside: +497.70%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $4.16
Upside: +2,784.62%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $4.70
Upside: +6,282.98%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $11.68
Upside: +396.58%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $359.58
Upside: -45.49%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.62
Upside: +5,949.38%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $70.44
Upside: -14.82%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $44.78
Upside: +45.15%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $118.97
Upside: -38.64%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $2.87
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $16.98
Upside: +359.36%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.19
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $9.01
Upside: +377.25%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $31.82
Upside: +6.85%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $12.18
Upside: +72.41%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $14.55
Upside: +9.97%